The Partnership Will Combine Each Company's Capabilities in Omics Research to Provide Biopharma Customers with Immunopeptidomics Insights for Drug Discovery Indivumed, developer of the world's leading
Dr Tom Collins Confirmed as ASEV President for 2021-2022 winebusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winebusiness.com Daily Mail and Mail on Sunday newspapers.
Share:
WEST LAFAYETTE, Ind., May 11, 2021 (GLOBE NEWSWIRE)
Inotiv, Inc. (NASDAQ:NOTV) (the Company , We , Our or Inotiv ), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that Kenneth Swart, Ph.D., has joined the Company as Vice President, Bioanalytical Sciences. Dr. Swart s arrival follows the closing of business acquisitions which expand the Company s pharmacology, immunohistochemistry and histopathology businesses, as well as the announcement of planned investments in laboratory sciences and solutions focused on assisting clients discover and develop novel therapies. At a time when our clients assets reflect a blend of traditional oral drug candidates to gene therapies and vaccines, the infusion of Dr. Swart s experience and leadership into our regulated bioanalytical, DMPK and cell & molecular biology team effort aligns with recent internal investments in our contract resea
Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences to Drive Growth of Expanding Laboratory Solutions Offerings
May 11, 2021 16:05 ET | Source: Inotiv, Inc. Inotiv, Inc.
WEST LAFAYETTE, Ind., May 11, 2021 (GLOBE NEWSWIRE)
Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that Kenneth Swart, Ph.D., has joined the Company as Vice President, Bioanalytical Sciences. Dr. Swart’s arrival follows the closing of business acquisitions which expand the Company’s pharmacology, immunohistochemistry and histopathology businesses, as well as the announcement of planned investments in laboratory sciences and solutions focused on assisting clients discover and develop novel therapies.